Repository logo

Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework

dc.contributor.authorLeece, Pamela
dc.contributor.authorKhorasheh, Triti
dc.contributor.authorZerger, Suzanne
dc.contributor.authorCorace, Kim
dc.contributor.authorNixon, Lara
dc.contributor.authorStrike, Carol
dc.contributor.authorBayomi, Ahmed M.
dc.contributor.authorMarks, Elisabeth
dc.contributor.authorHolowaty, Melissa
dc.contributor.authorCrichlow, Frank
dc.contributor.authorTaha, Sheena
dc.contributor.authorStraus, Sharon E.
dc.date.accessioned2025-10-28T04:47:30Z
dc.date.available2025-10-28T04:47:30Z
dc.date.issued2025-10-21
dc.date.updated2025-10-28T04:47:30Z
dc.description.abstractAbstract Background Few studies have systematically examined the barriers and facilitators to buprenorphine uptake, despite increasing opioid-related harms and guideline recommendations for use. The aim of the study was to use behaviour change frameworks to investigate barriers and facilitators to buprenorphine access and use from diverse perspectives in Ontario, Canada. Methods We conducted semi-structured face-to-face or telephone interviews with Ontarians including: people with living/lived expertise of opioid use (including family members), healthcare professionals, and organizational and system-level representatives. We used purposive sampling via existing professional networks to recruit participants with diverse experiences. The Theoretical Domains Framework (TDF) guided the data collection tool and analysis. Interviews were recorded, transcribed, coded, and underwent thematic analysis involving three study team members. Results We interviewed 28 participants between September 2019 and January 2020. Three predominant TDF domains were identified across all 4 levels: (1) environmental context/resources; (2) beliefs about consequences; (3) social influences. Key cross-cutting themes included access to comprehensive care, medication and treatment characteristics, confidence and experiences with buprenorphine, as well as supportive relationships and stigma/discrimination. Conclusions Multi-level barriers to optimal buprenorphine implementation continue in the face of the drug toxicity crisis. To counter the identified barriers and enhance facilitators, there is need for mentorship models of support for prescribing, flexibility in buprenorphine treatment requirements, better recognition of mental health and the social determinants of health in buprenorphine treatment, and comprehensive and integrated systems of care.
dc.identifier.citationAddiction Science & Clinical Practice. 2025 Oct 21;20(1):83
dc.identifier.urihttps://doi.org/10.1186/s13722-025-00610-w
dc.identifier.urihttp://hdl.handle.net/10393/50986
dc.language.rfc3066en
dc.rights.holderCrown
dc.titleMulti-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework
dc.typeJournal Article

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail ImageThumbnail Image
Name:
13722_2025_Article_610.pdf
Size:
966.02 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail ImageThumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description: